The U.S. Food and Drug Administration approved Eli Lilly’s monoclonal antibody donanemab, marketed as Kisunla, on July 15, 2024. The drug is intended exclusively for patients who have mild cognitive impairment or mild dementia due to Alzheimer’s disease—not for those with advanced disease or for preventive use.
Clinical trial results that formed the basis of the approval reveal a stark safety profile. Brain‑related adverse events—collectively known as amyloid‑related imaging abnormalities (ARIA)—including swelling and hemorrhage, occurred in 36.8 % of participants receiving donanemab. By comparison, 14.9 % of the placebo group experienced similar events, indicating that the drug roughly doubles the risk of serious brain complications.
These ARIA events are not minor. They can progress quickly to strokes, seizures, falls, and worsening cognitive function—the very outcomes the therapy aims to mitigate. In addition to ARIA, trial participants reported common side effects such as headache and allergic reactions, which, while less severe, add to the overall treatment burden for patients already coping with a debilitating illness.
The FDA’s advisory committee was divided on the issue, with a majority of members voting against approval. Public interest groups also voiced opposition during hearings, citing the safety concerns and questioning the drug’s efficacy. Nonetheless, the agency moved forward, citing the limited therapeutic options available to Alzheimer’s patients and the urgent need for treatments that can slow disease progression.
Donanemab works by targeting amyloid plaques in the brain, a hallmark of Alzheimer’s pathology. It is not a cure and does not reverse existing damage, but trial data suggest it can slow the decline in individuals with early‑stage symptoms. The benefit was observed only in the specific population studied—those with mild cognitive impairment or mild dementia—and did not extend to patients with more advanced disease.
With approval, Eli Lilly now faces the challenge of positioning a drug that demands careful patient selection and close monitoring. Physicians will need to weigh the potential cognitive benefit against a one‑in‑three chance of serious brain events, considering each patient’s age, overall health, and risk of falls. The agency’s decision also raises concerns about off‑label use in patients for whom no trial data exist, potentially exposing them to higher risks.
The approval mirrors earlier controversial decisions, such as the FDA’s clearance of Biogen’s Aduhelm, which also proceeded despite an advisory panel’s negative vote. Critics argue that these moves reflect a lowering of evidentiary standards, while supporters contend that waiting for flawless therapies is not an option for patients facing a rapidly progressing disease.
For families and clinicians, the decision now hinges on a difficult trade‑off: opting for a treatment that may modestly delay cognitive decline but carries a substantial risk of brain hemorrhage or swelling, or forgoing pharmacologic intervention and allowing the disease to follow its natural course. Individual factors—such as comorbid conditions, concurrent medications, and the patient’s ability to tolerate close imaging surveillance—will shape each recommendation.
The FDA’s clearance of donanemab expands the therapeutic arsenal for early‑stage Alzheimer’s, yet it opens a “door” that leads to complex clinical judgments. As the drug enters the market, ongoing real‑world monitoring will be essential to fully understand its risk‑benefit balance and to guide responsible prescribing practices.
